Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
| Autor: | Christian Taube, Tobias Welte, Benjamin Seeliger, Felix J.F. Herth, Karl-Christian Bergmann, Juergen Behr, Stephanie Korn, Nikolaus Kneidinger, Katrin Milger, Hendrik Suhling, Jan Fuge, Roland Buhl, Maren Schuhmann, Nora Drick, Benjamin Kendziora |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty medicine.drug_class Gastroenterology Pulmonary function testing 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Reslizumab Internal medicine Immunology and Allergy Medicine 0601 history and archaeology Adverse effect Interleukin 5 060102 archaeology biology business.industry 06 humanities and the arts Benralizumab 030228 respiratory system chemistry biology.protein Corticosteroid Antibody business Mepolizumab medicine.drug |
| Zdroj: | Journal of Asthma and Allergy. 13:605-614 |
| ISSN: | 1178-6965 |
| DOI: | 10.2147/jaa.s270298 |
| Popis: | Background Anti-IL-5 antibodies represent an established therapy for severe eosinophilic asthma (SEA), but some patients show inadequate response. The objective of this study was to assess the effects of a switch to anti-IL-5Rα therapy in patients with inadequate response to anti-IL-5 therapy. Methods In this retrospective multi-centre, real-life study, we analysed all SEA patients switched from anti-IL-5 to anti-IL-5Rα therapy due to inadequate response or intolerability. Pulmonary function tests, blood gas analyses, asthma control tests (ACT) and oral corticosteroid (OCS) usage were analysed and compared at three timepoints: baseline (BL, before anti-IL-5 therapy), timepoint 1 (T1, under anti-IL-5 therapy) and timepoint 2 (T2, under anti-IL-5Rα therapy). Results Of 665 patients treated with anti-IL-5 antibodies, 70 were switched to anti-IL-5Rα and 60 were included in the analysis. Median treatment duration was 8 months [IQR 5; 15] for anti-IL-5 and 5 months [IQR 4; 6] for anti-IL-5Rα therapy. FEV1 was 61% of predicted at BL [IQR 41; 74], 61% [IQR 43; 79] at T1 and 68% [IQR 49; 87] at T2 (pT1-T2=0.011). ACT score was 10 [IQR 8; 13], 16 [IQR 10; 19] and 19 [IQR 14; 22], respectively (both p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|